Categories Earnings, Health Care

Magellan Health (Nasdaq: MGLN) announces fiscal 2019 earnings outlook

Fortune-500 company Magellan Health, Inc. (NASDAQ: MGLN) today announced its fiscal 2019 outlook.

The healthcare giant now sees net revenue of $7.2-$7.5 billion generating a net income of $52-$79 million. Earnings is expected to be $2.14-$3.25 per share, while adjusted earnings is touted to be $3.70-$4.69 a share.

“Over the last few years, Magellan Health has evolved considerably by building our successful strategy to focus on the management of complex populations, specialty healthcare and pharmacy,” said CEO Barry M. Smith.

According to the CEO, Magellan “has significant earnings power” in its current portfolio. However, the company does admit that its margins are not competitive enough. “As a result, we have begun a multi-year margin improvement plan,” said Barry Smith.

“Entering the year, we are highly focused on execution of our key business priorities and multi-year profitability improvement” – CFO Jonathan N. Rubin

Segment profit for 2019 is expected to be $270-$290 million on favorable impacted by new business raking in $600 million in revenue, same- store growth, healthcare contracts, administrative cost reductions.

However, these factors are touted to be pulled down by contract terminations with year-over-year revenue impact of about $660 million and lower levels of discretionary benefits in 2018.

“Entering the year, we are highly focused on execution of our key business priorities and multi-year profitability improvement,” said CFO Jonathan N. Rubin.

Magellan Health also reiterated its FY18 guidance that it announced with third-quarter earnings on Nov.7. The company expected to announce its fourth-quarter results before market hours on Feb. 28, 2019.

 

 

Follow our Google News edition to get the latest stock market, earnings, and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top